Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PersonalisPSNL +5.09%59 14-Day RSI is 71.73 as of Jul. 15, 2026. GuruFocus rates PSNL with a GF Score™ of 59/100 and a GF Value™ of $2.08 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Personalis ranks worse than 97.7% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-15), Personalis's 14-Day RSI is 71.73.
The industry rank for Personalis's 14-Day RSI or its related term are showing as below:
PSNL's 14-Day RSI is ranked worse than 97.7% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.56
vs PSNL: 71.73
Personalis (NAS:PSNL) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Personalis 14-Day RSI Related Terms
PSNL vs CDNA, OPK, NEO: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Personalis's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Personalis 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Personalis's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Personalis (PSNL) has a 14-Day RSI of 71.73 as of Jul. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Personalis and its competitors. According to the industry distribution chart, Personalis ranks #212 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 97.7%.
Is Personalis' 14-Day RSI too high?
Personalis' current 14-Day RSI is 71.73. The Medical Diagnostics & Research industry median 14-Day RSI is 48.56. Personalis' value of 71.73 is 47.7% above this industry median. Based on the distribution chart, Personalis ranks #212 out of 217 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Personalis has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Personalis' 14-Day RSI compare to CDNA and OPK?
According to the Medical Diagnostics & Research industry distribution chart, Personalis ranks #212 out of 217 companies for 14-Day RSI. This places Personalis in the lower half of its industry. The industry median 14-Day RSI is 48.56. Personalis' value of 71.73 is 47.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 48.56, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Personalis's current 14-Day RSI of 71.73 is 47.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Personalis and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 48.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Personalis's current 14-Day RSI is 71.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Personalis stock overvalued right now?
Based on GuruFocus' analysis, Personalis (PSNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.08, compared to a current price of $15.79 — trading 659.1% above its estimated fair value. The current 14-Day RSI is 71.73 and 47.7% above the Medical Diagnostics & Research industry median of 48.56. Personalis' overall GF Score™ is 59/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Personalis (PSNL), the current 14-Day RSI is 71.73 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Personalis (PSNL) Overvalued in 2026?
Based on GuruFocus' analysis, Personalis stock appears to be overvalued.
The current stock price of $15.79 is trading 659.1% above its estimated GF Value™ of $2.08.
GuruFocus considers Personalis to be Significantly Overvalued.
Key valuation signals for PSNL:
14-Day RSI: 71.73
GF Value™: $2.08 vs. price of $15.79 (659.1% above fair value)
Industry Position: 47.7% above the Medical Diagnostics & Research median (#212 of 217)
No single metric tells the full story. See the PSNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
59GF Score
Get the complete analysis for PSNL
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSNL has been successfully added to your 
